Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06539182 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. 2 versions Re-verified since Nov 24, 2025, no change to tracked fieldsv4-v5
  2. Site details revised at 5 of 17 sites Eligibility criteria shortened, about 3 wordsv3 Show 1 more changeShow less
    • Eligibility criteria shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites revised (17)v2 See this version in full on ClinicalTrials.gov ↗
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will treat patients with CLL/SLL whose disease comes back or is not responding to prior therapy, or if they can not bear side effects of the prior treatment. This study will assess the anti-tumor activity of DZD8586 as monotherapy. It will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body.
Trial Details
NCT Number NCT06539182
Lead Sponsor Dizal Pharmaceuticals
Conditions Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment 155 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov